Skip to main content
Premium Trial:

Request an Annual Quote

Lion Posts Ballooning Net Loss, Modest Revenue Growth in Q4; May Sell iD3: Jun 5, 2002

Click here for an updated version of this article.

 

NEW YORK, June 5 - Lion Bioscience today reported ballooning fourth-quarter net loss as a doubling in R&D overpowered modest revenue growth.

 

In addition, Lion, signaling a change in business strategy, said it may sell off its drug-discovery unit in an effort to reign in net loss and reach profitability.

 

Total revenue in the quarter ended March 31 increased to €11 million, or roughly $10.3 million, from €7.8 million in the year-ago period, Lion said.

 

Research and development expenses in the fourth quarter 2002 nearly doubled to €16 million from €8.8 million year over year. As a result, net loss for the quarter swelled to €23.4 million, or €1.22 per share, from €3.5 million, or €.19 per share, one year ago, the company added.

 

Lion said it had €19.2 million cash and cash equivalents as of March 31.

The German bioinformatics company indicated it is actively looking for a partner or investor for its drug-discovery unit, and may even sell the business outright in a move to improve profitability. The firm said it plans to concentrate less on its iD3 platform and instead focus on its core IT business.

Lion CEO Friedrich von Bohlen said at a news conference in Heidelberg that the company is in talks to find a solution for the drug-discovery business and wants to reach an agreement by the end of the year, Dow Jones Newswires reported this morning.

The firm reiterated its goal of breaking even by the end of fiscal 2004, and expects "moderate" revenue growth for the current fiscal year.

 

Click here for more information.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.